StratifAI

StratifAI is a precision oncology company based in Dresden, Germany, founded in 2023.

The company focuses on developing AI-powered biomarker tests and multimodal artificial intelligence models to enhance cancer diagnostics, particularly in breast cancer prognostication. StratifAI's mission is to provide accurate insights to oncologists, ultimately improving patient outcomes. The company's flagship product, PolarisTM Breast, is an AI test that analyzes histology images to assess metastatic risk in early breast cancer and evaluate the benefits of adjuvant chemotherapy. This technology is designed to deliver faster results and lower costs compared to traditional genomic assays. StratifAI also offers customizable AI solutions for biomarker discovery and digital oncology tools aimed at optimizing cancer treatment. The company collaborates with healthcare providers and pharmaceutical companies to support treatment decision-making and accelerate drug development.